Merck has announced that its Phase 3 KEYLYNK-001 trial met its primary endpoint of progression-free survival (PFS) in patients with advanced epithelial ovarian cancer. The study evaluated KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or without bevacizumab, as a first-line treatment for people with BRCA non-mutated advanced epithelial ovarian cancer. “For people living with ovarian cancer, there remains an unmet…
ConTIPI Medical and EVERSANA have announced the U.S. commercial launch of ProVate, a new non-surgical device for women experiencing pelvic organ prolapse (POP). ProVate, a ready-to-use, disposable device for patients’ at-home use, is now available for physicians across the U.S. to prescribe. It is inserted vaginally in small dimensions within a disposable applicator, very similar to the concept of the menstrual tampon…
A new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine recommends that the National Institutes of Health (NIH) establish a new institute focused on women’s health, supported by $15.7 billion in new funding over five years. The report reveals that only 8.8 percent of NIH grant spending from 2013 to 2023 focused on women’s health research, with funding…
WHAM (Women’s Health Access Matters) has announced the launch of the WHAM Investment Collaborative, bringing together multibillion-dollar funds to accelerate innovation in women’s health. The initiative aims to address the significant funding gap in women’s health, where women-founded companies currently receive only 2% of venture capital funding. “This is a largely untapped market with tremendous potential for return,” said Carolee Lee, CEO…
Cure has released its 2024 Women’s Health Benchmark Report highlighting that established scientific expertise, robust clinical data, and previous commercial experience are crucial factors for raising capital in women’s health. “In a world where evidence-based medicine is the currency, the paucity of data about sex-linked differences in disease, drug responses, medtech efficacy and health outcomes is a major handicap when seeking funding,”…
Ultrahuman has announced the launch of its Cycle & Ovulation PowerPlug, a new fertility tracking feature available at no cost to Ring AIR users. The technology integrates multiple biomarkers including skin temperature, resting heart rate, and heart rate variability to track ovulation. “Most fertility tracking today is either inconvenient, expensive, or both. Women often have to use two apps, pay for two…
MasterClass has announced “The Magic of Menopause,” a new course featuring Oscar winner Halle Berry and four leading women’s health experts aimed at breaking stigmas around menopause. “I am so honored to launch the first-ever women’s health class on MasterClass. It’s time we dismantle the culture of silence and shame around this life stage that affects half of the population,” said Berry.…
ModifyHealth, a provider of medically tailored meals and nutritional counseling, has raised $13.5 million in Series C funding led by the Dohmen Company Foundation through its Dohmen Impact Investment Fund. Existing investors RC Capital and Nashville Capital Network also participated in the round. “Dohmen Company Foundation is pleased to welcome ModifyHealth as our newest partner in the fight against diet-related disease,” said…
